Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a report released on Thursday, Benzinga reports. They currently have a $7.00 price target on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 135.69% from the company’s current price.
Other equities analysts have also issued research reports about the company. JMP Securities restated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Jefferies Financial Group reissued a “buy” rating and issued a $8.00 price objective (up from $2.00) on shares of Taysha Gene Therapies in a report on Tuesday, May 14th. Chardan Capital reissued a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Monday. Finally, Piper Sandler initiated coverage on Taysha Gene Therapies in a report on Tuesday, April 9th. They issued an “overweight” rating and a $9.00 price objective on the stock. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $7.00.
Check Out Our Latest Research Report on TSHA
Taysha Gene Therapies Stock Performance
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last posted its earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. The firm had revenue of $3.41 million during the quarter, compared to analysts’ expectations of $3.70 million. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. During the same period in the previous year, the business posted ($0.28) EPS. On average, analysts anticipate that Taysha Gene Therapies will post -0.43 EPS for the current year.
Hedge Funds Weigh In On Taysha Gene Therapies
Hedge funds and other institutional investors have recently made changes to their positions in the company. Howard Capital Management Inc. purchased a new position in shares of Taysha Gene Therapies in the fourth quarter valued at approximately $25,000. Victory Capital Management Inc. purchased a new position in shares of Taysha Gene Therapies in the fourth quarter valued at approximately $28,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Taysha Gene Therapies in the fourth quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Taysha Gene Therapies in the fourth quarter valued at approximately $38,000. Finally, Cannon Global Investment Management LLC purchased a new position in shares of Taysha Gene Therapies in the first quarter valued at approximately $69,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.
Taysha Gene Therapies Company Profile
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Featured Stories
- Five stocks we like better than Taysha Gene Therapies
- Best Aerospace Stocks Investing
- Costco Split History: Is it Time for Costco to Split Again?
- P/E Ratio Calculation: How to Assess Stocks
- Signet Jewelers Stock Poised for Rebound After Earnings Drop
- Consumer Discretionary Stocks Explained
- Airship AI Lands New Contract: Stock Soars 16% and More to Come
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.